Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?
Increasing evidence implicates an important role for a variety of bone marrow derived cells (BMDCs) in tumor angiogenesis and metastatic tumor growth. These cells are derived either from the hematopoietic or mesenchymal cell lineage, and they are distinguished, in part, by the expression of the panhematopoietic marker - CD45. Some of these cell populations can colonize tumors perivascularily, and appear to promote angiogenesis and tumor cell proliferation by paracraine mechanisms, whereas others can contribute "directly" to the growth of tumor vessel capillaries or metastases. In this review we focus in particular on the role of hemangiocytes or recruited bone marrow derived circulating cells (RBCCs) in neovascularization, the contribution of VEGFR1+ hematopoietic stem cells and endothelial precursor cells in metastasis, and the involvement of myeloid derived suppressor CD11b+/Gr-1+ cells in the resistance of tumors to certain antiangiogenic drugs, e.g., VEGF blocking antibodies.
Shaked
Yuval
Y
Molecular Pharmacology, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. yshaked@tx.technion.ac.il
Voest
Emile E
EE
D000818:Animals; D001854:Bone Marrow Cells / Q000502:physiology*; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm; D042783:Endothelial Cells / Q000502:physiology*; D055018:Hemangioblasts / Q000502:physiology*; D006801:Humans; D022423:Myeloid Cells / Q000502:physiology; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology*; D009389:Neovascularization, Pathologic